RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/30487290http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/30487290http://www.w3.org/2000/01/rdf-schema#comment"Kras-driven non-small-cell lung cancers (NSCLCs) are a leading cause of death with limited therapeutic options. Many NSCLCs exhibit high levels of Ezh2, the enzymatic subunit of polycomb repressive complex 2 (PRC2). We tested Ezh2 inhibitors as single agents or before chemotherapy in mice with orthotopic Kras-driven NSCLC grafts, which homogeneously express Ezh2. These tumors display sensitivity to EZH2 inhibition by GSK126 but also amplify an inflammatory program involving signaling through NF-κB and genes residing in PRC2-regulated chromatin. During this process, tumor cells overcome GSK126 antiproliferative effects. We identified oncogenes that may mediate progression through an in vivo RNAi screen aimed at targets of PRC2/NF-κB. An in vitro compound screening linked GSK126-driven inflammation and therapeutic vulnerability in human cells to regulation of RNA synthesis and proteostasis. Interestingly, GSK126-treated NSCLCs in vivo also showed an enhanced response to a combination of nimesulide and bortezomib. Thus, Ezh2 inhibition may restrict cell proliferation and promote defined adaptive responses. Targeting these responses potentially improves outcomes in Kras-driven NSCLCs."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.org/dc/terms/identifier"doi:10.1084/jem.20180801"xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Morris B."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Schmitt M.J."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Beijersbergen R.L."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Gargiulo G."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Cesaroni M."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"van Lohuizen M."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Serresi M."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Hulsman D."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Company C."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Proost N."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Lieftink C."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/author"Siteur B."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/date"2018"xsd:gYear
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/name"J Exp Med"xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/pages"3115-3135"xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/title"Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities."xsd:string
http://purl.uniprot.org/citations/30487290http://purl.uniprot.org/core/volume"215"xsd:string
http://purl.uniprot.org/citations/30487290http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/30487290
http://purl.uniprot.org/citations/30487290http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/30487290
http://purl.uniprot.org/uniprot/#_F2YMM1-mappedCitation-30487290http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/30487290
http://purl.uniprot.org/uniprot/#_A0A090N8E9-mappedCitation-30487290http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/30487290
http://purl.uniprot.org/uniprot/#_A0A0N4SVY1-mappedCitation-30487290http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/30487290